Rockwell Medical Q4 revenue $19.3M, up 26% YoY; net loss narrows to $2.4M; guides FY2023 sales $78-82M

ROCKWELL MEDICAL, INC.

Q4 2022 revenue $19.3M (+26% YoY); full-year revenue $72.8M (+17.6% YoY), highest ever.
Net loss Q4 $2.4M ($0.20/share) vs $8.9M ($1.05) in Q4 2021; full-year net loss $18.7M ($1.89) vs $32.7M ($3.83).
Debt reduced to $10.0M at year-end from $21.6M at end of 2021; cash used in ops improved to $17.4M from $33.5M.
2023 guidance: net sales $78-82M, gross profit $7-9M; focus on hemodialysis concentrates growth and profitability.
Reacquired distribution rights from Baxter for >700 hemodialysis customers; new CEO Mark Strobeck joined July 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ROCKWELL MEDICAL, INC. reported 2023 results: revenue $78.0 Million to $82.0 Million. Guidance initiated.

Period: 2023
Revenue: $78.0 Million to $82.0 Million
Guidance: initiated
Result: guidance update

Exact text from the filing

Rockwell projects its 2023 guidance as follows: Net Sales $78.0 Million to $82.0 Million Gross Profit $7.0 Million to $9.0 Million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2022 results: revenue $72.8 million, net income $18.7 million, EPS $1.89 per share.

Period: the twelve months ended December 31, 2022
Revenue: $72.8 million
Net income: $18.7 million
EPS: $1.89 per share
Result: reported results

Exact text from the filing

of revenue growth with new high of $19.3 million in the fourth quarter 2022, representing a 26.0% increase over same period in 2021 • Exceeded annual revenue guidance generating $72.8 million in 2022, representing a 17.6% increase year-over-year and the highest full-year revenue to date for the Company • Reduced debt to $10.0 million at December 31, 2022, representing

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2022 results: revenue $19.3 million, net income $2.4 million, EPS $0.20 per share.

Period: the three months ended December 31, 2022
Revenue: $19.3 million
Net income: $2.4 million
EPS: $0.20 per share
Result: reported results

Exact text from the filing

--- Rockwell Medical Announces Fourth Quarter and Full-Year 2022 Financial and Operational Results • Achieved third consecutive quarter of revenue growth with new high of $19.3 million in the fourth quarter 2022, representing a 26.0% increase over same period in 2021 • Exceeded annual revenue guidance generating $72.8 million in 2022, representing a 17.6%

View on SEC.gov

Browse all earnings releases →

ROCKWELL MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-009762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.